NCT06620848View on ClinicalTrials.gov

A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Biliary Tract Cancer
Interventions
DRUG

HRS-4642 monotherapy

HRS-4642 will be administrated per dose level in which the patients are assigned.

DRUG

HRS-4642 and adebrelimab combination therapy

HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.

Trial Locations (1)

200020

RECRUITING

Shanghai Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER